# Almirall

Source: https://onco.cc/companies/almirall/  
OnCo record `almirall` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Almirall is a Barcelona dermatology company whose cancer-related product is tirbanibulin ointment for actinic keratosis, approved in the United States in 2020 and in Europe in 2021.

## Summary

Almirall, listed on the Spanish stock exchange, is a pharmaceutical company focused on medical dermatology. Its contribution to cancer prevention is tirbanibulin (Klisyri), a topical microtubule inhibitor for actinic keratosis of the face and scalp, the precancerous lesion that can progress to squamous cell skin cancer, approved by the FDA in December 2020 and the European Commission in 2021. OnCo records it so that its phase 3 trials resolve to a sponsor page.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Almirall, S.A.
- Tags: ctgov-sponsor
- HQ: Barcelona
- Type: pharma
- Website: https://www.almirall.com

## Sources

- Official website: https://www.almirall.com
- ClinicalTrials.gov: trials led by Almirall: https://clinicaltrials.gov/search?lead=Almirall
- Wikipedia: https://en.wikipedia.org/wiki/Almirall

## Connected records

- cancers: [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)

---
JSON: https://onco.cc/api/v1/entities/almirall.json